1. Skip to main content
  2. A+
  3. A
  4. A-
  5. A
  6. हिन्दी
BARC


Mandate

The Radiopharmaceuticals Division is committed to fulfilling the following mandates:
1. Production, Radiochemical Processing and Supply of Reactor Produced Radionuclides:
Irradiation of targets for production of various radionuclides, radiochemical processing to obtain the irradiated targets in desired chemical form and supplying the radiochemicals to users in Health-care, Industry, Agriculture and research through BRIT.
2. Research, Development, Demonstration and Deployment of State-of-the-art Radiopharmaceuticals:
Research and Development on radiopharmaceuticals with rigorous radiochemical studies and biological evaluation to formulate potential new products for clinical applications. Demonstration and Deployment of the developed radiopharmaceuticals in human health-care in collaboration with various Nuclear Medicine Centers and Hospitals.
3. Production and Supply of Sealed Sources:
Tiny sealed radioactive sources; to be used either as reference sources or for the treatment of cancers (for brachytherapy) are prepared and supplied to various users in Industry and Hospitals.


Highlights


10/2020

From April 2019 to Feb 2021, a total of 1164 units of irradiation were carried out in Dhruva reactor and Apsara -U reactor. These and other irradiation activities are coordinated by the Irradiation Service Group of RPhD utilizing Dhruva and Apsara-U research reactors. Facilities like tray rod, self serve and pneumatic carrier with different flux and time are made available for users depending on the need. Self serve facility for short term irradiation has helped fulfill the demands of a large number of researchers in India.



10/2020

Brachytherapy is a specialized modality of cancer treatment. Iodine-125 seed sources are supplied to authorized users for the brachytherapy of eye and prostate cancer. They are prepared by incorporation of 20-130MBq Iodine-125 on palladium coated silver wires, then sealed by laser-welding within 50 micron thick titanium tubes. In case of eye brachytherapy, 10-20 sources are fixed on a gold plaque placed over eye tumor for a pre-fixed duration. For prostate brachytherapy, 60 to 100 sources are permanently implanted in the prostate gland using MICK applicator. These sources have benefited more than 175 eye cancer patients and 12 prostate cancer patients.



10/2020

Around 500 Ci of [177Lu] Lutetium chloride solution is produced per year and directly deployed as radiopharmaceutical precursor to a number of nuclear medicine centers across India for preparation of 177Lu-DOTATATE, 177Lu-PSMA-617 and other 177Lu-radiopharmaceuticals for cancer therapy. Around 800-1000 cancer patients were treated at RMC and TMH each year using [177Lu]Lu-chloride supplied from RPhD.



2/2020

National Science Day 2020 (25-28 Feb) was focused on the theme of Radiation and Radioisotopes in Healthcare. RPhD had a major role in the successful organization of this public awareness event. A careful selection of model exhibits, layman-friendly presentations and theme-relevant skits gave the participants an insight into DAE\'s valuable contributions to the health sector. This program was much appreciated, especially by the young participants from educational institutions across the state.



2/2020

National Science Day 2020 (25-28 Feb) was focused on the theme of Radiation and Radioisotopes in Healthcare. RPhD had a major role in the successful organization of this public awareness event. A careful selection of model exhibits, layman-friendly presentations and theme-relevant skits gave the participants an insight into DAE\'s valuable contributions to the health sector. This program was much appreciated, especially by the young participants from educational institutions across the state.



2/2020

National Science Day 2020 (25-28 Feb) was focused on the theme of Radiation and Radioisotopes in Healthcare. RPhD had a major role in the successful organization of this public awareness event. A careful selection of model exhibits, layman-friendly presentations and theme-relevant skits gave the participants an insight into DAE\'s valuable contributions to the health sector. This program was much appreciated, especially by the young participants from educational institutions across the state.




Facilities


Technologies Developed

(22-02-2021) 99mTc-HYNIC-[cyclo(RGDfk)]2 for detection of active malignant tumors


Malignant tumors aggressively stimulate the formation of new blood vessels to feed the growing tumor mass. Arginylglycylaspartic acid (RGD) is known to bind with the new vasculature. Thus, a technetium-99m labeled form of RGD can detect / image growing malignant tumors of several origins and help in the prognosis/staging of such tumors, which makes it a very useful radiotracer in nuclear medicine.



(22-02-2021) 90Y-Hydroxyapatite for symptomatic relief in rheumatoid arthritis


This is a yttrium-90 labeled form of Hydroxyapatite (Pentacalcium hydroxide triphosphate), a locally applied particulate radiopharmaceutical which has palliative / therapeutic application. It is used for symptomatic pain management of rheumatoid arthritis (RA) patients by administration in the affected synovial joints, minimizing the need for steroid medication with the accompanying side-effects. The greater beta-energy of yttrium-90 allows for more effective pain relief in larger joints like the knee.



(22-02-2021) 177Lu-Hydroxyapatite for symptomatic relief in rheumatoid arthritis


This is a lutetium-177 labeled form of Hydroxyapatite (Pentacalcium hydroxide triphosphate), a locally applied particulate radiopharmaceutical which has palliative / therapeutic application. It is used for symptomatic pain management of rheumatoid arthritis (RA) patients by administration in the affected synovial joints, minimizing the need for steroid medication with the accompanying side-effects. The longer decay half-life of lutetium-177 allows for logistical advantage in transport to nuclear medicine therapy centers in remote regions.



(22-02-2021) 177Lu-DOTMP for pain relief of bone metastases in cancer


This is a lutetium-177 labeled form of DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid), which has palliative / therapeutic application in cancer. It is used for pain reduction and management of bone metastases of cancers of multiple origins, helping to improve the quality of life of patients for the period of survival. The longer decay half-life of lutetium-177 allows for logistical advantage in transport to nuclear medicine therapy centers in remote regions.



(22-02-2021) 188Re-DEDC/lipiodol for therapy of liver cancer


This is a rhenium-188 labeled form of Diethyl Dithiocarbamate (DEDC), a lipophilic complex which is then incorporated into lipiodol, a mixture of iodinated esters of fatty acids. The resultant formulation has therapeutic application. It is used for Selective Internal Radiation Therapy (SIRT) of liver cancer by the procedure known as Trans-arterial Radio-embolization (TARE). It has advantageous properties for TARE and is useful in nuclear medicine centers or centralized radiopharmacies that possess radionuclide generator for rhenium-188.



(22-02-2021) 188Re-HEDP for pain relief of bone metastases in cancer


This is a rhenium-188 labeled form of Hydroxyethyl diphosphonate (HEDP), which has palliative / therapeutic application in cancer. It is used for pain reduction and management of bone metastases of cancers of multiple origins, helping to improve the quality of life of patients for the period of survival.



(22-02-2021) 131I-Lipiodol for therapy of liver cancer


This is an iodine-131 labeled form of lipiodol, a mixture of iodinated esters of fatty acids, which has therapeutic application. It is used for Selective Internal Radiation Therapy (SIRT) of liver cancer by the procedure known as Trans-arterial Radio-embolization.



(22-02-2021) 99mTc-UBI (29-41) for imaging of deep-seated infections


This is a technetium-99m labeled complex of ubiquicidin, a peptide that specifically binds with bacterial cell wall structures, useful in nuclear medicine as a radiotracer for detection/imaging of deep-seated infections.



(22-02-2021) 68Ga-DOTATOC for detection of neuroendocrine tumors


This is a gallium-68 labeled somatostatin analog, useful in nuclear medicine as a radiotracer for positron emission tomography (PET) imaging of neuroendocrine tumors.



(22-02-2021) 99mTc-Tetrofosmin for imaging of cardiac perfusion


This is a technetium-99m labeled myocardial perfusion radiotracer, useful in nuclear medicine for detection/imaging of cardiac perfusion abnormalities like ischemia or infarct.



(22-02-2021) 99mTc-HYNIC-TOC for detection of neuroendocrine tumors


This is a technetium-99m labeled somatostatin analog, useful in nuclear medicine as a radiotracer for detection/imaging of neuroendocrine tumors.




Show Cases

BARC

DAE-Radiopharmaceuticals Committee (DAE-RPC) approved 'Freeze-dried Kits', developed at Radiopharmaceuticals Division, for the easy and convenient formulation of various Diagnostic and Therapeutic Radiopharmaceuticals

BARC

DAE-Radiopharmaceuticals Committee (DAE-RPC) approved 'Freeze-dried Kits', developed at Radiopharmaceuticals Division, for the easy and convenient formulation of various Diagnostic and Therapeutic Radiopharmaceuticals

21-Jan-2022